The il-1 beta modulating antibody, gevokizumab, limits left ventricular remodeling and coronary endothelial dysfunction following myocardial ischemia/reperfusion in diabetic rats
EUROPEAN JOURNAL OF HEART FAILURE（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要